Carmell Therapeutics Corporation Total Liabilities
Carmell Therapeutics Corporation total liabilities. Based on the latest financial reports, Carmell Therapeutics Corporation (CTCX) has total liabilities worth $7.14 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Carmell Therapeutics Corporation liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Carmell Therapeutics Corporation (2021–2024)
Total liabilities of Carmell Therapeutics Corporation from 2021 to 2024. This chart illustrates how Carmell Therapeutics Corporation's total liabilities have evolved over time, based on quarterly financial data.
Carmell Therapeutics Corporation Competitors by Total Liabilities
The table below lists competitors of Carmell Therapeutics Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Traws Pharma Inc
NASDAQ:TRAW
|
USA | $9.78 Million |
|
Strategem Capital Corp
V:SGE
|
Canada | CA$54.00K |
|
CARLSON INV. ZY 13
F:2HB
|
Germany | €1.12 Million |
|
UNITH LTD.
F:CM30
|
Germany | €1.61 Million |
|
Kane Biotech Inc
V:KNE
|
Canada | CA$3.48 Million |
|
Resources & Energy Group Ltd
AU:REZ
|
Australia | AU$1.61 Million |
|
OLB Group Inc
NASDAQ:OLB
|
USA | $6.80 Million |
|
Acurx Pharmaceuticals LLC
NASDAQ:ACXP
|
USA | $2.83 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Carmell Therapeutics Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Carmell Therapeutics Corporation's balance sheet.
Liquidity & Leverage Metrics
Carmell Therapeutics Corporation Total Liabilities Ratios Explained
Carmell Therapeutics Corporation total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Carmell Therapeutics Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Carmell Therapeutics Corporation (2021–2024)
The table below shows the annual total liabilities of Carmell Therapeutics Corporation from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.19 Million | -84.22% |
| 2023-12-31 | $39.20 Million | -0.86% |
| 2022-12-31 | $39.54 Million | +27.00% |
| 2021-12-31 | $31.13 Million | -- |
About Carmell Therapeutics Corporation
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on … Read more